home

LATEST ONCOPRESCRIBE UPDATES

• FDA Approves LIBTAYO® in Combination with Chemotherapy for Non-Small Cell Lung Cancer

• TAFINLAR® and MEKINIST® versus OPDIVO® plus YERVOY® for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial

• Association of Gut Microbiome with Immune Checkpoint Inhibitor Response in Advanced Melanoma

• NUBEQA® Combination Improves Overall Survival in Metastatic Hormone Sensitive Prostate Cancer

• XPOVIO® (selinexor): A Treatment Approved for Multiple Myeloma as Early as First Relapse

• BRUKINSA® Superior to IMBRUVICA® in Relapsed/Refractory CLL/SLL

• RNF43 Mutations Predict Response to Anti-BRAF/EGFR Combination Therapy in BRAF V600E Metastatic Colorectal Cancer

• FDA Approves TECVAYLI® for Relapsed or Refractory Multiple Myeloma

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• TIBSOVO® - for Acute Myeloid Leukemia

• Single Agent LUMAKRAS® - for Non Small Cell Lung Cancer

• KEYTRUDA® - for Malignant Melanoma

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• KEYTRUDA® plus INLYTA® - for Renal Cancer

Curbside Consultation

Multiple Myeloma Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• TTP, HUS and aHUS: Different diseases – Different treatments

• HER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE